Azenta, Inc. (LON:0HQ1)

Revenue by Geography

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2017 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2017 - 2020
United States Revenue	363.27M	366.21M	Log In	Log In	Log In	Upgrade
North America Revenue	-	-	Log In	Log In	Log In	Upgrade
Africa Revenue	-	61.96M	Log In	Log In	Log In	Upgrade
China Revenue	57.14M	58.26M	Log In	Log In	Log In	Upgrade
United Kingdom Revenue	33.28M	27.45M	Log In	Log In	Log In	Upgrade
Rest of Europe Revenue	106.11M	102.77M	Log In	Log In	Log In	Upgrade
Asia Pacific/ Other Revenue	31.62M	39.67M	Log In	Log In	Log In	Upgrade
Revenue (Other)	77.41M	-	Log In	Log In	Log In	Upgrade
Revenue (Total)	668.82M	656.32M	Log In	Log In	Log In	Upgrade

Revenue Breakdown

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2017 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2017 - 2020
Sample Management Solutions Revenue	323.65M	318.65M	Log In	Log In	Log In	Upgrade
Multiomics Revenue	262.05M	254.55M	Log In	Log In	Log In	Upgrade
B Medical Revenue	-	83.13M	Log In	Log In	Log In	Upgrade
Revenue (Other)	83.13M	-	Log In	Log In	Log In	Upgrade
Revenue (Total)	668.82M	656.32M	Log In	Log In	Log In	Upgrade

Revenue Breakdown 2

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2017 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2017 - 2020
Life Sciences Products Revenue	-	-	Log In	Log In	Log In	Upgrade
Life Sciences Services Revenue	-	-	Log In	Log In	Log In	Upgrade
Revenue (Total)	668.82M	656.32M	Log In	Log In	Log In	Upgrade

Revenue Breakdown 3

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2017 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2017 - 2020
Multiomics Revenue	262.05M	254.55M	Log In	Log In	Log In	Upgrade
Core Products Revenue	196.98M	196.73M	Log In	Log In	Log In	Upgrade
Sample Repository Solutions Revenue	126.67M	121.91M	Log In	Log In	Log In	Upgrade
B Medical Revenue	-	83.13M	Log In	Log In	Log In	Upgrade
Revenue (Total)	668.82M	656.32M	Log In	Log In	Log In	Upgrade

Adjusted EBIT

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2017 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2017 - 2020
Sample Management Solutions Adjusted Operating Income	28.26M	10.84M	Log In	Log In	Log In	Upgrade
Multiomics Adjusted Operating Income	-11.80M	-8.00M	Log In	Log In	Log In	Upgrade
B Medical Systems Adjusted Operating Income	-	-5.67M	Log In	Log In	Log In	Upgrade
Operating Income (Other)	-86.47M	-197.86M	Log In	Log In	Log In	Upgrade
Operating Income (Total)	-70.02M	-200.68M	Log In	Log In	Log In	Upgrade

Adjusted EBIT 2

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2017 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2017 - 2020
Life Sciences Product Adjusted Operating Income	-	-	Log In	Log In	Log In	Upgrade
Life Sciences Services Adjusted Operating Income	-	-	Log In	Log In	Log In	Upgrade
Operating Income (Total)	-70.02M	-200.68M	Log In	Log In	Log In	Upgrade

Key Performance Indicators

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2017 - 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	2017 - 2020
Organic Revenue Growth	-	-2.00%	Log In	Log In	Log In	Upgrade

Updated Jun 30, 2025. Data Source: Fiscal.ai.